27R Stock Overview
RaySearch Laboratories AB (publ), a medical technology company, develops software solutions for cancer treatment in the Asia-Pacific, the Middle East, the Americas, Europe, and Africa.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 27R from our risk checks.
RaySearch Laboratories AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr9.81 |
| 52 Week High | kr10.52 |
| 52 Week Low | kr4.76 |
| Beta | 1.23 |
| 1 Month Change | 2.62% |
| 3 Month Change | 21.41% |
| 1 Year Change | 53.52% |
| 3 Year Change | 10.47% |
| 5 Year Change | -13.26% |
| Change since IPO | -15.71% |
Recent News & Updates
Recent updates
Shareholder Returns
| 27R | DE Healthcare Services | DE Market | |
|---|---|---|---|
| 7D | -5.3% | -5.0% | -1.7% |
| 1Y | 53.5% | -25.1% | -0.2% |
Return vs Industry: 27R exceeded the German Healthcare Services industry which returned -23% over the past year.
Return vs Market: 27R exceeded the German Market which returned 0.9% over the past year.
Price Volatility
| 27R volatility | |
|---|---|
| 27R Average Weekly Movement | 4.8% |
| Healthcare Services Industry Average Movement | 4.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 27R has not had significant price volatility in the past 3 months.
Volatility Over Time: 27R's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 388 | Johan Lof | www.raysearchlabs.com |
RaySearch Laboratories AB (publ), a medical technology company, develops software solutions for cancer treatment in the Asia-Pacific, the Middle East, the Americas, Europe, and Africa. It develops and markets RayStation, a treatment planning system; RayPlan, a treatment planning system for supporting a range of treatment planning activities for 3D-CRT, IMRT, VMAT, tomotherapy, and electron beam radiation therapy; and RayCare, an oncology information. In addition, it offers µ-RayStation, a software platform for planning and evaluation in small animal irradiation research; RayCommand, a treatment control system that serves as link between the treatment machine and the treatment planning and oncology information systems; and RayIntelligence, a cloud-based oncology analytics system that turns patient data into insights.
RaySearch Laboratories AB (publ) Fundamentals Summary
| 27R fundamental statistics | |
|---|---|
| Market cap | €335.61m |
| Earnings (TTM) | €7.00m |
| Revenue (TTM) | €87.78m |
47.9x
P/E Ratio3.8x
P/S RatioIs 27R overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 27R income statement (TTM) | |
|---|---|
| Revenue | kr1.02b |
| Cost of Revenue | kr106.58m |
| Gross Profit | kr915.58m |
| Other Expenses | kr834.01m |
| Earnings | kr81.57m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 26, 2024
| Earnings per share (EPS) | 2.38 |
| Gross Margin | 89.57% |
| Net Profit Margin | 7.98% |
| Debt/Equity Ratio | 0.1% |
How did 27R perform over the long term?
See historical performance and comparison